Literature DB >> 17687158

Who should be sent for genetic testing in hereditary colorectal cancer syndromes?

Henry T Lynch1, C Richard Boland, Miguel A Rodriguez-Bigas, Christopher Amos, Jane F Lynch, Patrick M Lynch.   

Abstract

Genetic testing is being adopted increasingly to identify individuals with germline mutations that predispose to hereditary colorectal cancer syndromes. Deciding who to test and for which syndrome is of concern to members of the GI oncology community, molecular geneticists, and genetic counselors. The purpose of this review is to help provide guidelines for testing, given that the results influence syndrome diagnosis and clinical management. Although family history may determine whether testing is appropriate and may direct testing to the most informative family member, evolving clinicopathologic features can identify individual patients who warrant testing. Thus, although the usual absence of clinical premonitory signs in hereditary nonpolyposis colorectal cancer (or Lynch syndrome) adds difficulty to its diagnosis, use of the Amsterdam Criteria and Bethesda Guidelines can prove helpful. In contrast, premonitory stigmata such as pigmentations in Peutz-Jeghers syndrome and the phenotypic features of familial adenomatous polyposis aid significantly in syndrome diagnosis. We conclude that the physician's role in advising DNA testing is no small matter, given that a hereditary cancer syndrome's sequelae may be far reaching. Genetic counselors may be extremely helpful to the practicing gastroenterologist, oncologist, or surgeon; when more specialized knowledge is called for, referral can be made to a medical geneticist and/or a medical genetics clinic.

Entities:  

Mesh:

Year:  2007        PMID: 17687158     DOI: 10.1200/JCO.2006.10.3119

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  26 in total

Review 1.  Lynch syndrome diagnostics: decision-making process for germ-line testing.

Authors:  E Lastra; M García-González; B Llorente; C Bernuy; M J Barrio; L Pérez-Cabornero; M Durán; C García-Girón
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

2.  Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities.

Authors:  Larissa A Meyer; Meaghan E Anderson; Robin A Lacour; Anuj Suri; Molly S Daniels; Diana L Urbauer; Graciela M Nogueras-Gonzalez; Kathleen M Schmeler; David M Gershenson; Karen H Lu
Journal:  Obstet Gynecol       Date:  2010-05       Impact factor: 7.661

3.  Making sense of missense in Lynch syndrome: the clinical perspective.

Authors:  Henry T Lynch; Thomas Jascur; Stephen Lanspa; C Richard Boland
Journal:  Cancer Prev Res (Phila)       Date:  2010-10-26

Review 4.  Diagnosis and management of hereditary colorectal cancer syndromes: Lynch syndrome as a model.

Authors:  Henry T Lynch; Jane F Lynch; Thomas A Attard
Journal:  CMAJ       Date:  2009-08-04       Impact factor: 8.262

5.  Comparison of the clinical prediction model PREMM(1,2,6) and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer.

Authors:  Fay Kastrinos; Ewout W Steyerberg; Judith Balmaña; Rowena Mercado; Steven Gallinger; Robert Haile; Graham Casey; John L Hopper; Loic LeMarchand; Noralane M Lindor; Polly A Newcomb; Stephen N Thibodeau; Sapna Syngal
Journal:  Gut       Date:  2012-02-16       Impact factor: 23.059

6.  Assessing pathogenicity: overview of results from the IARC Unclassified Genetic Variants Working Group.

Authors:  Sean V Tavtigian; Marc S Greenblatt; David E Goldgar; Paolo Boffetta
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

7.  Mismatch repair protein expression and colorectal cancer in Hispanics from Puerto Rico.

Authors:  Wilfredo E De Jesus-Monge; Carmen Gonzalez-Keelan; Ronghua Zhao; Stanley R Hamilton; Miguel Rodriguez-Bigas; Marcia Cruz-Correa
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

Review 8.  Clinical implications of microsatellite instability in sporadic colon cancers.

Authors:  Frank A Sinicrope; Daniel J Sargent
Journal:  Curr Opin Oncol       Date:  2009-07       Impact factor: 3.645

9.  Utility of p16 immunohistochemistry for the identification of Lynch syndrome.

Authors:  Artemio Payá; Cristina Alenda; Lucía Pérez-Carbonell; Estefanía Rojas; José-Luis Soto; Carmen Guillén; Adela Castillejo; Victor M Barberá; Alfredo Carrato; Antoni Castells; Xavier Llor; Montserrat Andreu; Jim Koh; Greg H Enders; Susana Benlloch; Rodrigo Jover
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

10.  Importance of age of onset in pancreatic cancer kindreds.

Authors:  Kieran A Brune; Bryan Lau; Emily Palmisano; Marcia Canto; Michael G Goggins; Ralph H Hruban; Alison P Klein
Journal:  J Natl Cancer Inst       Date:  2010-01-12       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.